Physician profile
Michelle Tobin
NPI 1396049847
$762.93
in general payments reported to CMS, 2019-2025
11 companies · $47.13 in 2025
The $47.13 reported for 2025 was less than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2022: $179 · 2023: $47.52 · 2024: $101 · 2025: $47.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $195.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $128.47 | 2019 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2022 | |
| Gilead Sciences, INC. | $118.66 | 2019 | |
| Biogen, INC. | $78.41 | 2023-2024 | Spinraza, Skyclarys |
| Ns Pharma, INC. | $53.50 | 2022 | |
| Sarepta Therapeutics, INC. | $43.44 | 2023-2025 | Elevidys |
| Takeda Pharmaceuticals U.S.A., INC. | $31.87 | 2024-2025 | Gattex, Eohilia |
| Itf Therapeutics LLC | $21.54 | 2024 | |
| Mirum Pharmaceuticals, INC. | $20.65 | 2024 | Livmarli |
| Shire North American Group INC | $16.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Tobin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.